Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.77M
2: EX-2.3 Amendment to No. 2 to the Asset Purchase Agreement HTML 50K
Between Amgen and Celgene
3: EX-2.4 Letter Agreement - Treatment of Certain Product HTML 244K
Inventory
4: EX-4.29 Description of Securities HTML 166K
9: EX-10.10 Form of Restricted Stock Unit Agreement HTML 67K
10: EX-10.11 Form of Cash-Settled Restricted Stock Unit HTML 65K
Agreement
11: EX-10.14 Second Amendment to Supplemental Retirement Plan HTML 41K
12: EX-10.21 Second Amendment to Nonqualified Deferred HTML 41K
Compensation Plan
5: EX-10.4 Form of Grant of Stock Option Agreement HTML 213K
13: EX-10.41 Collaboration Agreement HTML 466K
14: EX-10.42 Guarantee Agreement HTML 71K
6: EX-10.5 Form of Restricted Stock Unit Agreement HTML 211K
7: EX-10.7 Form of Performance Unit Agreement HTML 202K
8: EX-10.8 Director Equity Incentive Program HTML 69K
15: EX-21 Subsidiaries of the Company HTML 45K
16: EX-31 Rule 13A-14(A) Certifications HTML 54K
17: EX-32 Section 1350 Certifications HTML 43K
101: R1 Cover page HTML 112K
54: R2 Consolidated Statements of Income HTML 101K
71: R3 Consolidated Statements of Comprehensive Income HTML 64K
150: R4 Consolidated Balance Sheets HTML 117K
99: R5 Consolidated Balance Sheets (Parenthetical) HTML 45K
53: R6 Consolidated Statements of Stockholders' Equity HTML 91K
70: R7 Consolidated Statements of Stockholders' Equity HTML 41K
(Parenthetical)
148: R8 Consolidated Statements of Cash Flows HTML 120K
103: R9 Summary of significant accounting policies HTML 74K
149: R10 Acquisitions HTML 75K
104: R11 Revenues HTML 160K
52: R12 Stock-based compensation HTML 135K
73: R13 Defined contribution plan HTML 41K
147: R14 Income taxes HTML 155K
102: R15 Earnings per share HTML 63K
51: R16 Collaborations HTML 58K
72: R17 Investments HTML 197K
151: R18 Inventories HTML 48K
100: R19 Property, plant and equipment HTML 71K
25: R20 Goodwill and intangible assets HTML 96K
75: R21 Leases HTML 81K
124: R22 Other current assets and accrued liabilities HTML 60K
110: R23 Financing arrangements HTML 154K
24: R24 Stockholders' equity HTML 181K
74: R25 Fair value measurement HTML 220K
123: R26 Derivative instruments HTML 237K
109: R27 Contingencies and commitments HTML 172K
23: R28 Quarterly financial data (Unaudited) HTML 83K
76: R29 Subsequent events HTML 43K
68: R30 Schedule Ii - Valuation and Qualifying Accounts HTML 59K
48: R31 Summary of significant accounting policies - HTML 139K
(Policies)
106: R32 Acquisitions - (Tables) HTML 63K
152: R33 Revenues (Tables) HTML 159K
69: R34 Stock-based compensation (Tables) HTML 128K
49: R35 Income taxes (Tables) HTML 153K
107: R36 Earnings per share (Tables) HTML 62K
153: R37 Investments - (Tables) HTML 192K
67: R38 Inventories (Tables) HTML 50K
50: R39 Property, plant and equipment (Tables) HTML 73K
85: R40 Goodwill and other intangible assets - (Tables) HTML 93K
33: R41 Leases - (Tables) HTML 81K
111: R42 Other current assets and accrued liabilities HTML 63K
(Tables)
125: R43 Financing arrangements (Tables) HTML 141K
86: R44 Stockholders' equity (Tables) HTML 177K
34: R45 Fair value measurement - (Tables) HTML 201K
112: R46 Derivative instruments - (Tables) HTML 230K
126: R47 Contingencies and commitments - (Tables) HTML 46K
84: R48 Quarterly financial data (Unaudited) (Tables) HTML 82K
36: R49 Summary of significant accounting policies - HTML 61K
Narrative (Details)
46: R50 Acquisitions - Narrative (Details) HTML 106K
65: R51 Acquisitions - Otezla (Details) HTML 62K
138: R52 Acquisitions - Aggregate Consideration Paid HTML 62K
(Details)
89: R53 Revenues - Narrative (Details) HTML 164K
45: R54 Revenues - Customer Concentration, Product Sales HTML 60K
(Details)
63: R55 Stock-based compensation (Textual) (Details) HTML 97K
135: R56 Stock-based compensation (Components of HTML 51K
Stock-based Compensation Expense) (Details)
88: R57 Stock-based compensation (Summary of RSUs) HTML 65K
(Details)
44: R58 Stock-based compensation Stock-based compensation HTML 56K
(Summary of Stock Options) (Details)
66: R59 Stock-based compensation (Summary of Stock HTML 92K
Options) (Details)
130: R60 Stock-based compensation (Weighted-average HTML 50K
Assumptions) (Details)
119: R61 Defined contribution plan (Details) HTML 40K
30: R62 Income taxes (Income Before Income Taxes) HTML 46K
(Details)
81: R63 Income taxes (Provision for Income Taxes) HTML 69K
(Details)
129: R64 Income taxes (Components of Deferred Tax Assets HTML 78K
and Liabilities) (Details)
116: R65 Income taxes (Textual) (Details) HTML 74K
27: R66 Income taxes (Reconciliation of Total Gross HTML 54K
Amounts of UTBs) (Details)
80: R67 Income taxes (Reconciliation of Federal Statutory HTML 74K
Tax Rate) (Details)
133: R68 Earnings per share (Details) HTML 68K
113: R69 Collaborations - Novartis AG (Details) HTML 63K
93: R70 Collaborations - Bayer HealthCare Pharmaceuticals HTML 57K
Inc. (Details)
142: R71 Investments - Schedule (Details) HTML 84K
56: R72 Investments - Fair Values by Classification HTML 51K
(Details)
40: R73 Investments - Available-for-sale (Details) HTML 46K
94: R74 Investments - Fair Values by Contractual Maturity HTML 55K
(Details)
145: R75 Investments - Unrealized Losses and Fair Values HTML 83K
(Details)
59: R76 Investments - Equity Securities (Details) HTML 42K
41: R77 Investments - Limited Partnership Investments HTML 44K
(Details)
98: R78 Inventories (Details) HTML 50K
140: R79 Property, plant and equipment (Schedule) (Details) HTML 90K
91: R80 Property, plant and equipment (Geographic HTML 48K
Information) (Details)
141: R81 Goodwill and other intangible assets - Goodwill HTML 46K
Roll Forward (Details)
55: R82 Goodwill and other intangible assets - HTML 69K
Identifiable Intangible Assets (Details)
38: R83 Goodwill and other intangible assets - Narrative HTML 55K
(Details)
96: R84 Leases - Narrative (Details) HTML 63K
146: R85 Leases - Summary of Leases (Details) HTML 47K
60: R86 Leases - Components of Lease Costs (Details) HTML 45K
43: R87 Maturities of Lease Liabilities (Details) HTML 62K
97: R88 Leases - Cash and Noncash Information of Leases HTML 43K
(Details)
139: R89 Leases - Prior to adoption (Details) HTML 59K
132: R90 Other current assets and accrued liabilities HTML 49K
Schedule of Other Assets (Details)
120: R91 Schedule of Accrued Liabilities (Details) HTML 53K
31: R92 Financing arrangements (Principal Amounts and HTML 242K
Carrying Value of Long-term Borrowings) (Details)
83: R93 Financing arrangements (Debt Issuances) (Details) HTML 61K
127: R94 Financing arrangements (Debt Repayments) (Details) HTML 78K
115: R95 Financing arrangements (Interest Rate and HTML 91K
Cross-currency Swaps) (Details)
26: R96 Financing arrangements (Shelf Registration HTML 65K
Statements and Other Facilities) (Details)
78: R97 Financing arrangements (Contractual Maturities of HTML 58K
Long-term Debt) (Details)
134: R98 Financing arrangements (Interest Costs) (Details) HTML 41K
114: R99 Stockholders' equity (Stock Repurchase Program) HTML 55K
(Details)
39: R100 Stockholders' equity (Dividends) (Details) HTML 47K
57: R101 Stockholders' equity (Components of AOCI) HTML 81K
(Details)
143: R102 Stockholders' equity (Accumulated Other HTML 50K
Comprehensive Income (Loss), Textual) (Details)
92: R103 Stockholders' equity (Reclassifications out of HTML 93K
AOCI) (Details)
42: R104 Stockholders' equity (Other) (Details) HTML 47K
58: R105 Fair value measurement - (Fair Value of Financial HTML 160K
Assets and Liabilities on Recurring Basis)
(Details)
144: R106 Fair value measurement - Narrative (Details) HTML 75K
95: R107 Derivative instruments - Narrative (Details) HTML 60K
37: R108 Derivative instruments - (Cross-currency Swaps) HTML 73K
(Details)
62: R109 Derivative instruments - (Effective Portion of HTML 50K
Unrealized Gain (Loss)) (Details)
82: R110 Derivative instruments - (Hedged Liabilities and HTML 52K
Cumulative Amount) (Details) (Details)
29: R111 Derivative instruments - (Summary of Income and HTML 72K
Expense Line Items) (Details)
118: R112 Derivative instruments - (Fair Value of HTML 71K
Derivatives) (Details)
131: R113 Contingencies and commitments (Sensipar ANDA HTML 45K
Patent Litigation) (Details)
79: R114 Contingencies and commitments (Sandoz Patent HTML 47K
Litigation) (Details)
28: R115 Contingencies and commitments (Repatha Patent HTML 46K
Litigation) (Details)
117: R116 Contingencies and commitments (NEUPOGEN Patent HTML 45K
Litigation) (Details)
128: R117 Contingencies and commitments (EPOGEN Patent HTML 47K
Litigation) (Details)
77: R118 Contingencies and commitments (AMJEVITA Patent HTML 41K
Litigation) (Details)
32: R119 Contingencies and commitments (KANJINTI Patent HTML 42K
Litigation) (Details)
90: R120 Contingencies and commitments (MVASI Patent HTML 46K
Litigation) (Details)
137: R121 Contingencies and commitments (Additional HTML 53K
Information) (Details)
64: R122 Contingencies and commitments (U.S. Repatriation HTML 55K
Tax Commitments) (Details)
47: R123 Quarterly financial data (Unaudited) (Details) HTML 68K
87: R124 Subsequent events - Narrative (Details) HTML 50K
136: R125 Schedule Ii - Valuation and Qualifying Accounts HTML 48K
(Details)
108: R9999 Uncategorized Items - amgn-12312019x10kq42019.htm HTML 39K
35: XML IDEA XML File -- Filing Summary XML 278K
122: XML XBRL Instance -- amgn-12312019x10kq42019_htm XML 5.74M
105: EXCEL IDEA Workbook of Financial Reports XLSX 175K
19: EX-101.CAL XBRL Calculations -- amgn-20191231_cal XML 375K
20: EX-101.DEF XBRL Definitions -- amgn-20191231_def XML 1.36M
21: EX-101.LAB XBRL Labels -- amgn-20191231_lab XML 2.86M
22: EX-101.PRE XBRL Presentations -- amgn-20191231_pre XML 1.85M
18: EX-101.SCH XBRL Schema -- amgn-20191231 XSD 319K
121: JSON XBRL Instance as JSON Data -- MetaLinks 591± 892K
61: ZIP XBRL Zipped Folder -- 0000318154-20-000017-xbrl Zip 1.06M
‘EX-10.14’ — Second Amendment to Supplemental Retirement Plan
This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]
